The Global Oral Antidiabetic Drugs Market Is Expected To Grow At A CAGR Of 4.22%

With the presence of a large pool of participants, the global oral anti-diabetic drug market is displaying a highly competitive business landscape, finds a new research report by Zion Market Research (ZMR). Novo Nordisk, Abbott Laboratories, Sanofi S.A., Novartis International AG, and Pfizer Inc. are few of the key vendors of oral anti-diabetic drug across the world. These players are focusing aggressively on innovation, as well as on including advanced technologies in their existing products. Over the coming years, they are also expected to take up partnerships and mergers and acquisitions as their key strategy for business development, states the oral anti-diabetic drug market study.

Citing an instance, in August 2018, researchers proved the effectiveness of Novo Nordisk’s oral diabetes drug Ozempic in reducing the level of blood sugar in the diabetics with renal injury. Reportedly, Novo conducted a twenty-six week phase three clinical trial PIONEER 5 on 324 individuals with type-2 diabetes & kidney damage. The firm found that there was reduction in blood sugar level in many of these individuals when they were treated with Ozempic, an oral semaglutide.

As estimated in this report, the global Oral Antidiabetic Drugs market size was valued USD 44.59 billion in 2023 and is expected to rise to USD 64.68 billion by 2032 at a CAGR of 4.22%. The main drug types available in this oral anti-diabetic drug market are sulfonylureas, alpha-glucosidase inhibitors, meglitinides, and biguanides. Among them, the demand for sulfonylureas is relatively higher and the trend is anticipated to remain so over the next few years, notes the oral anti-diabetic drug market research report.

Sedentary Lifestyles & Rise In Cases Of Diabetes To Leverage Market Revenue

“Inactive lifestyle, obesity, and higher stress along with growing occurrence of diabetes are anticipated to boost the demand for oral anti-diabetic drugs over the coming years,” says the author of this oral anti-diabetic drug market study. Apart from this, technological breakthroughs and medical compensation facilities are likely to impel the growth of oral anti-diabetic drug market in the years ahead.

The gigantic rise in the drug costs, however, is projected to restrict the expansion of oral anti-diabetic drug market in the forthcoming years. Nevertheless, the increase in the R&D activities and tremendous potential for oral anti-diabetic drug market to grow will chart a profitable roadmap for the business over the ensuing years, thereby normalizing the negative impact of hindrances on the oral anti-diabetic drug market development, reports the study.

Introduction Of New Drugs & Government Support To Impact Regional Growth

Regionally, North America has been leading the worldwide oral anti-diabetic drug market and is anticipated to continue on the dominant position in the years to come, states the oral anti-diabetic drug market study. Supportive government policies and launching of innovative products is the main factor behind the dominance of the North America oral anti-diabetic drug industry.

Browse the full “Oral Antidiabetic Drugs Market By Drugs Class (Sulfonylureas (Glimepiride, Gliclazide, Glyburide, Others), Meglitinides, Repaglinide, Nateglinide, Biguanides (Metformin, Others), Alpha-glucosidase inhibitors (Acarbose, Voglibose, Others), Others, By Type (Type 1 Diabetes, Type 2 diabetes), By End User (Hospital, Pharmacy Store, Drug Store, Diabetics Treatment Centres, Others) - Global Industry Perspective, Comprehensive Analysis And Forecast, 2024 – 2032.” Report at https://www.zionmarketresearch.com/report/oral-anti-diabetic-drugs-market

The global oral anti-diabetic drug market is segmented as follows:

By Drugs Class

• Sulfonylureas (Glimepiride, Gliclazide, Glyburide, Others)
• Meglitinides
• Repaglinide
• Nateglinide
• Biguanides (Metformin, Others)
• Alpha-glucosidase inhibitors (Acarbose, Voglibose, Others)
• Others

By Type

• Type 1 Diabetes
• Type 2 diabetes

By End User

• Hospital
• Pharmacy Store
• Drug Store
• Diabetics Treatment Centres
• Others

Oral Antidiabetic Drugs Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com